Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up

NCT07678268 is registered in ClinicalTrials.gov with Instituto Mexicano del Seguro Social as lead sponsor.

NCT NCT07678268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07678268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up
Lead sponsor
Instituto Mexicano del Seguro Social
Phase
Phase 4
Overall status
Recruiting
Start date
July 10, 2025
Completion date
December 10, 2026
Enrollment
78 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antiretroviral therapy, hiv infection, lentivirus infections